MissionIR Articles
-
Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development Company…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Offers Innovative Solution in Multibillion and Growing Market
Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020,…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models
Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now…
-
Predictive Oncology Inc. (NASDAQ: POAI) Taps Its Chairman to be CEO
Current POAI Chairman J. Melville (“Mel”) Engle has been appointed to CEO position Engle has held executive positions throughout his career at leading pharma and medical device companies, including Dey L.P. (a subsidiary of Merck…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big…
-
Predictive Oncology’s (NASDAQ: POAI) Helomics Exec Talks AI, Big Data and Biology During Podcast Appearance
Convergence of AI, big data and biology allows Helomics to test drugs on living tumor tissue rather than artificial systems Helomics model evaluates multiple measurements in powerful multi-omics approach to cancer research Knowledge encapsulated by…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Appoints Board Chair as New CEO
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as…
-
Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Working on Gen 3 Fluid-to-Drain Liquid Waste Management System for Hospitals
Fluid management systems, accessories market forecast at 13.6% CAGR to $16.1 billion by 2025 Skyline Medical’s STREAMWAY(R) System disrupts today’s standard of manually moving waste fluid for disposal STREAMWAY Systems eliminates waste transport, disposal costs,…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases FY 2020 Financial Results, Business Highlights
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has reported business highlights and financial results for the year ended Dec. 31, 2020. Highlights discussed…
-
Predictive Oncology Inc. (NASDAQ: POAI) Hits Milestone in AI Platform Development for Ovarian Cancer
Cancer screenings, treatments declined during COVID-19 pandemic, highlighting need for personalized therapies to improve outcomes Comprehensive genomic, transcriptomic sequencing of patient samples complete, patient outcome data obtained from UPMC-Magee Project is template for future partnerships…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Development of Newly Designed System for Direct-to-Drain Fluid Waste Management
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical Division is renewing the development of a new Generation 3…
-
Predictive Oncology Inc. (NASDAQ: POAI) Announces Fundraising Agreements to Raise Estimated $25M
POAI completes two separate fundraising initiatives: private placement, direct offering. Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively. Predictive Oncology plans to use funds to pay off debt as well as…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leveraging AI, Proprietary Database to Improve Outcomes for Patients of Today and Tomorrow
Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients
Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing…
-
Predictive Oncology Inc. (NASDAQ: POAI) Receives ‘Buy’ Rating from Litchfield Hills Research in First Analyst Coverage Report
Calling POAI undervalued, Litchfield initiates coverage of Predictive Oncology with Buy rating, $3 price target The drug industry is changing as tools and technology to tailor drugs emerge, regulatory bodies focus on patients’ experiences, perspectives,…
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiaries Ink Significant Contract, Announce Sale of Media to Top Medical Centers
POAI subsidiary inks contract with significant pharmaceutical company TumorGenesis announces sale of media to research medical centers in New York City, Boston Potential market for 3D cancer cell culture media expected to reach $3.2 billion sales…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes $17.6M Private Placement; Reaches Key Milestones in Developing AI-Driven Model of Ovarian Cancer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery closed on its previously announced private placement of common stock and warrants. Priced at-the-market under Nasdaq rules,…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $17.6M Private Placement
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.4M Registered Direct Offering, Announces Breakthrough Discoveries
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had closed on its previously announced registered direct offering. The offering, comprised of…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.4M Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced its entry into definitive agreements with several institutional and accredited investors for the issuance…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial